StreetInsider.com News Articles

Spyre Therapeutics presents IBD antibody data at UEGW 2026

Sun, 18 Oct 2026 09:30:12 -0400

Spyre Therapeutics, Inc. (NASDAQ: SYRE) presented clinical and preclinical data at United European Gastroenterology Week (UEGW) 2026 in Barcelona, according to a company statement.

The presentations marked the first scientific congress disclosure of clinical data across all three of Spyre's inflammatory bowel disease antibodies: SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23). The three antibodies are being tested as monotherapies and pairwise combinations in the company's ongoing SKYLINE Phase 2 platform trial.

An oral presentation titled "Efficacy and Safety of Half-Life Extended Antibodies SPY001, SPY002, and SPY003 for Induction Treatment of Moderately to Severely Active Ulcerative Colitis" was delivered Oct. 18 by Silvio

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

Sun, 18 Oct 2026 09:30:00 -0400

WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced presentations at United European Gastroenterology Week (UEGW) 2026 in Barcelona. The presentations include the first scientific congress presentation of clinical data across all three of Spyre’s IBD antibodies—SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23)—which are now being tested as monotherapies and pairwise combinations in the SKYLINE study, as well as new preclinical data

Spyre Therapeutics Announces Clinical and Preclinical Data Presentations at United European Gastroenterology Week (UEGW) 2026

Sun, 18 Oct 2026 09:30:00 -0400

UBS Starts Spyre (SYRE) at Buy

Mon, 12 Oct 2026 02:17:22 -0400

UBS analyst Alice Nettleton initiates coverage on Spyre (NASDAQ: SYRE) with a Buy rating and a price target of $120.00.

The analyst comments: “We initiate Spyre Therapeutics (SYRE) with a Buy rating and $120 PT. We view SYRE as the best way to play IBD combination therapies within a market we estimate could reach $40-50B in 2035. Its portfolio of combinations across IL-23, a4B7, and TL1A provides multiple shots on goal and, in our view, favorable odds that at least one regimen succeeds clinically and commercially. Instead of concentrating on a single outcome for the future of IBD, SYRE provides exposure

UBS Starts Spyre (SYRE) at Buy

Mon, 12 Oct 2026 02:17:22 -0400

UBS analyst Alice Nettleton initiates coverage on Spyre (NASDAQ: SYRE) with a Buy rating and a price target of $120.00.

Form SCHEDULE 13D/A Spyre Therapeutics, Inc. Filed by: Fairmount Funds Management LLC

Fri, 09 Oct 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20261009/27172171.html

Jefferies reiterates Top Pick on Spyre

Fri, 09 Oct 2026 10:05:20 -0400

Jefferies analyst Akash Tewari reiterated a Buy rating and a $129.00 price target on Spyre Therapeutics (NASDAQ: SYRE)

Tewari cited data to be presented at UEGW 2026, including a real-world study called COMBEII from Spain that examined 249 patients with inflammatory bowel disease treated with advanced combination therapies. The most common combinations in the study were upadacitinib plus ustekinumab at 15% and upadacitinib plus vedolizumab at 11%.

Spyre currently has three combination treatments in development, each expected to produce Phase 2 data in 2027: SPY130 (IL-23 and a4b7), SPY230 (IL-23 and TL1A), and SPY120 (a4b7 and TL1A).

The analyst wrote "we think this

Form 8-K Spyre Therapeutics, Inc. For: Oct 05

Wed, 07 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261007/27158248.html

Form 424B5 Spyre Therapeutics, Inc.

Tue, 06 Oct 2026 16:42:00 -0400

si-local-file:///var/storage/secattach/20261006/27156074.html

Spyre Therapeutics prices $350M stock offering at $85 per share

Mon, 05 Oct 2026 20:14:06 -0400

Spyre Therapeutics, Inc. (Nasdaq: SYRE) has priced a public offering of 4,117,648 shares of common stock at $85.00 per share, according to a press release from the clinical-stage biotechnology company.

The offering is expected to generate approximately $350.0 million in gross proceeds before underwriting discounts, commissions, and other expenses. The underwriters have been granted a 30-day option to purchase up to an additional approximately $52.5 million in shares under the same terms.

The offering is expected to close on or about October 7, 2026, subject to customary closing conditions.

Spyre stated it intends to use the net proceeds to advance programs in gastroenterology,

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

Mon, 05 Oct 2026 20:13:00 -0400

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $350.0 million, before deducting underwriting discounts and commissions

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

Mon, 05 Oct 2026 20:13:00 -0400

Spyre Therapeutics stock falls on public offering launch

Mon, 05 Oct 2026 16:31:18 -0400

Investing.com -- Spyre Therapeutics Inc (NASDAQ:SYRE) shares fell 2.9% in after-hours trading Monday following the company's announcement of an underwritten public offering of its common stock.

The clinical-stage biotechnology company said it has commenced the offering on Nasdaq, with underwriters receiving a 30-day option to purchase an additional 15% of the shares offered under the same terms and conditions.

Jefferies, TD Cowen, Leerink Partners and Stifel are acting as joint book-running managers for the proposed offering, while LifeSci Capital serves as passive bookrunner.

Spyre intends to use the net proceeds to advance its programs in Gastroenterology, Rheumatology, and Dermatology, including

Spyre Therapeutics stock falls on public offering launch

Mon, 05 Oct 2026 16:31:18 -0400

Investing.com -- Spyre Therapeutics Inc (NASDAQ:SYRE) shares fell 2.9% in after-hours trading Monday following the company's announcement of an underwritten public offering of its common stock.

Jefferies, TD Cowen, Leerink Partners and Stifel are acting as joint book-running managers for the proposed offering, while LifeSci Capital serves as passive bookrunner.

Spyre intends to use the net proceeds to advance its programs in Gastroenterology, Rheumatology, and Dermatology, including

Form 424B5 Spyre Therapeutics, Inc.

Mon, 05 Oct 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20261005/27148873.html

Spyre Therapeutics launches public stock offering on Nasdaq

Mon, 05 Oct 2026 16:01:10 -0400

Spyre Therapeutics, Inc. (Nasdaq: SYRE), a clinical-stage biotechnology company based in Waltham, Mass., announced the launch of an underwritten public offering of its common stock, according to a press release.

The company plans to grant underwriters a 30-day option to purchase an additional 15% of the shares offered, under the same terms and conditions. The offering remains subject to market conditions, with no assurance on timing, size, or completion.

Spyre stated it intends to use the net proceeds to advance programs in gastroenterology, rheumatology, and dermatology, including funding for preclinical studies, clinical trials, manufacturing, and Phase 3 readiness. The company also plans

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

Mon, 05 Oct 2026 16:01:00 -0400

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase an additional 15% of the shares of common stock offered in the public offering

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock

Mon, 05 Oct 2026 16:01:00 -0400

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that it has commenced an underwritten public offering of its common stock. In addition, the Company is expected to grant the underwriters of the offering an option for a period of 30 days to purchase an additional 15% of the shares of common stock offered in the public offering

Form 4 Spyre Therapeutics, Inc. For: Oct 01 Filed by: Turtle Cameron

Fri, 02 Oct 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20261002/27144153.html

Form 4 Spyre Therapeutics, Inc. For: Oct 01 Filed by: King-Jones Heidy

Fri, 02 Oct 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20261002/27144156.html

Form 4 Spyre Therapeutics, Inc. For: Sep 30 Filed by: Burrows Scott L

Fri, 02 Oct 2026 21:29:00 -0400

si-local-file:///var/storage/secattach/20261002/27144152.html

Spyre Therapeutics Announces Grants of Inducement Awards

Fri, 02 Oct 2026 16:05:00 -0400

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 21,424 shares of common stock of Spyre and 6,604 restricted stock units (“RSUs”) to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity

Spyre Therapeutics Announces Grants of Inducement Awards

Fri, 02 Oct 2026 16:05:00 -0400

Form 144 Spyre Therapeutics, Inc. Filed by: Turtle Cameron

Thu, 01 Oct 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20261001/27136665.html

Form 144 Spyre Therapeutics, Inc. Filed by: King-Jones Heidy

Thu, 01 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261001/27136515.html